ArticleJournal of medicinal chemistry2025

RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236).

Zonghui Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.